Investor Presentation Updated March 2026 Disclaimer Forward-Looking Statements This presentation has been prepared by Lumexa Imaging Holdings, Inc. ("Lumexa Imaging," the "Company" or "we") and contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including our guidance fo ...

Core Insights - CapsoVision, Inc. has appointed David Garcia as Senior Vice President of Finance to support its growth phase [1][3] - Garcia brings over 20 years of financial leadership experience, including roles in corporate finance and capital markets [2] - The company aims to leverage Garcia's expertise in financial management and capital strategy to advance its development pipeline and achieve corporate milestones [3] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis [4] - The flagship product, CapsoCam Plus®, is a wire-free capsule endoscope that provides high-resolution visualization of the small bowel [4] - The upcoming product, CapsoCam Colon™, will enhance non-invasive colon imaging and polyp detection using advanced AI [4]

Core Insights - The FDA has cleared software advancements for Intuitive's Ion endoluminal system, enhancing navigation and access to advanced imaging for lung biopsy procedures [1][3]. Company Developments - Intuitive's Ion system features an ultra-thin, shape-sensing catheter that allows physicians to access small, hard-to-reach lung nodules for biopsy [2]. - The latest software release integrates artificial intelligence into the navigational workflow, improving accuracy and efficiency in lung biopsies [3][5]. - The AI-powered navigation addresses the challenge of CT-to-body divergence, allowing real-time adjustments during procedures [5][6]. Industry Context - Lung cancer remains the leading cause of cancer-related deaths globally and in the U.S., with early diagnosis linked to higher survival rates [4]. - The introduction of advanced imaging capabilities, including integrated tomosynthesis, aims to broaden access to imaging options for lung biopsies [7][8]. - As of June 30, 2025, over 900 Ion systems are operational in hospitals across 10 countries, with ongoing clinical studies involving more than 2,000 subjects [10][11].